Large-scale genome projects enter the clinic on both sides of the Atlantic.

G enetic testing has become more common in cancer care in recent years. However, nearly all such tests are limited to a few genetic alterations that affect patient responses to targeted agents. Now, several groups are working to expand that approach to more patients and more genes, including many with unknown function or import. Earlier this fall, researchers launched two programs designed to offer genetic testing to thousands of patients in routine care. Cancer Research UK is running one program, and Dana – Farber Cancer Institute and Brigham and Women ’ s Hospital in Boston are running the other. Together, the projects will probably speed uptake of genetic testing in regular cancer care, as well as provide the raw data that researchers need for future drug development and improved interventions.